THE EFFECT OF INTRAVESICAL ONABOTULINUM TOXIN A TREATMENT ON QUALITY OF LIFE IN PATIENTS WITH OVERACTIVE BLADDER

Tuğçe Arslanoğlu; Cenk Yaşa; Funda Güngör Uğurlucan

Makale detayları

THE EFFECT OF INTRAVESICAL ONABOTULINUM TOXIN A TREATMENT ON QUALITY OF LIFE IN PATIENTS WITH OVERACTIVE BLADDER

Yazarlar:

Tuğçe Arslanoğlu | Cenk Yaşa | Funda Güngör Uğurlucan

Yayıncı:

Istanbul University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

İstanbul Tıp Fakültesi Dergisi Vol.86 Issue 2, pp.109-116

Belge Tipi:

Makale

Yayın Tarihi:

3/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001287782

pISSN:

1305-6441

Anahtar kelimeler:

Özet:

 Objective: Overactive bladder OAB syndrome is common in women and negatively affects their quality of life. Our study aimed to evaluate the effect of intravesical onabotulinum toxin A injection on quality of life and urinary symptoms in patients with treatment resistant OAB syndrome. Material and Method: The treatment records of 20 patients with treatment-resistant OAB were reviewed. The patients were injected with a 1:1 solution of saline and 100 units of onabotulinum toxin A at 20 different points on the body, avoiding the bladder trigon. The following survey instruments were used to determine the patients quality of life before and after treatment: the Kings Health Questionnaire KHQ, the short-form Urodistress Inventory UDI 6, the short-form Incontinence Impact Questionnaire IIQ 7, the International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms Modules ICIQ FLUTS, the Female Sexual Function Index FSFI, and the Pelvic Organ ProlapseUrinary Incontinence Inquiry form PISQ-12. The pre-and post-treatment results of the questionnaires were then evaluated. Result: The uroflowmetry parameters indicated that the patients maximum urine flow rate decreased significantly after treatment, as did their KHQ scores on all but one item. Evaluation of their FSFI scores indicated no significant change after treatment; however, the other quality of life questionnaires used UDI-6, IIQ-7, ICIQ-FLUTS, and PISQ-12 revealed significant decreases, indicating an improvement in quality of life. Conclusion: When the patients short-term results were evaluated, it was found that this therapy reduced their symptoms and complaints, thus improving their quality of life. Although none of the patients in the sample group experienced complications, in some cases catheterization is necessary due to infection and increased residual urine. Intravesical onabotulinum toxin A injection is a cheap and easy-to-administer treatment for OAB that has not responded to other treatments and does not cause serious side effects.

 Objective: Overactive bladder OAB syndrome is common in women and negatively affects their quality of life. Our study aimed to evaluate the effect of intravesical onabotulinum toxin A injection on quality of life and urinary symptoms in patients with treatment resistant OAB syndrome. Material and Method: The treatment records of 20 patients with treatment-resistant OAB were reviewed. The patients were injected with a 1:1 solution of saline and 100 units of onabotulinum toxin A at 20 different points on the body, avoiding the bladder trigon. The following survey instruments were used to determine the patients quality of life before and after treatment: the Kings Health Questionnaire KHQ, the short-form Urodistress Inventory UDI 6, the short-form Incontinence Impact Questionnaire IIQ 7, the International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms Modules ICIQ FLUTS, the Female Sexual Function Index FSFI, and the Pelvic Organ ProlapseUrinary Incontinence Inquiry form PISQ-12. The pre-and post-treatment results of the questionnaires were then evaluated. Result: The uroflowmetry parameters indicated that the patients maximum urine flow rate decreased significantly after treatment, as did their KHQ scores on all but one item. Evaluation of their FSFI scores indicated no significant change after treatment; however, the other quality of life questionnaires used UDI-6, IIQ-7, ICIQ-FLUTS, and PISQ-12 revealed significant decreases, indicating an improvement in quality of life. Conclusion: When the patients short-term results were evaluated, it was found that this therapy reduced their symptoms and complaints, thus improving their quality of life. Although none of the patients in the sample group experienced complications, in some cases catheterization is necessary due to infection and increased residual urine. Intravesical onabotulinum toxin A injection is a cheap and easy-to-administer treatment for OAB that has not responded to other treatments and does not cause serious side effects.

 Objective: Overactive bladder OAB syndrome is common in women and negatively affects their quality of life. Our study aimed to evaluate the effect of intravesical onabotulinum toxin A injection on quality of life and urinary symptoms in patients with treatment resistant OAB syndrome. Material and Method: The treatment records of 20 patients with treatment-resistant OAB were reviewed. The patients were injected with a 1:1 solution of saline and 100 units of onabotulinum toxin A at 20 different points on the body, avoiding the bladder trigon. The following survey instruments were used to determine the patients quality of life before and after treatment: the Kings Health Questionnaire KHQ, the short-form Urodistress Inventory UDI 6, the short-form Incontinence Impact Questionnaire IIQ 7, the International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms Modules ICIQ FLUTS, the Female Sexual Function Index FSFI, and the Pelvic Organ ProlapseUrinary Incontinence Inquiry form PISQ-12. The pre-and post-treatment results of the questionnaires were then evaluated. Result: The uroflowmetry parameters indicated that the patients maximum urine flow rate decreased significantly after treatment, as did their KHQ scores on all but one item. Evaluation of their FSFI scores indicated no significant change after treatment; however, the other quality of life questionnaires used UDI-6, IIQ-7, ICIQ-FLUTS, and PISQ-12 revealed significant decreases, indicating an improvement in quality of life. Conclusion: When the patients short-term results were evaluated, it was found that this therapy reduced their symptoms and complaints, thus improving their quality of life. Although none of the patients in the sample group experienced complications, in some cases catheterization is necessary due to infection and increased residual urine. Intravesical onabotulinum toxin A injection is a cheap and easy-to-administer treatment for OAB that has not responded to other treatments and does not cause serious side effects.

 Amaç: Aşırı aktif mesane AAM, kadınlarda oldukça sık görülen ve hayat kalitesini olumsuz etkileyen bir sendromdur. Çalışmamızın amacı; tedaviye dirençli AAM sendromu olan hastalarda intravezikal onabotulinum toksin A enjeksiyonunun hastaların hayat kalitesine ve üriner semptomlarına olan etkisini değerlendirmektir. Gereç ve Yöntem: Çalışmaya medikal tedaviye dirençli toplam 20 hasta dahil edildi. Hastalara 1:1 oranda salin ile sulandırılıp 100 Ünite onabotulinum toksin A kullanılarak 20 farklı noktaya, mesane trigonundan kaçınılarak enjeksiyon yapılmıştır. Hastaların yaşam kalitelerini belirlemek için kullanılan King Sağlık Anketi KHQ, Ürogenital Distres Envanteri kısa formu UDI 6, İnkontinans Etki Anketi kısa formu IIQ 7, ICIQ-FLUTS, Kadın Cinsel Fonksiyon Endeksi formu FSFI, Pelvik Organ Prolapsusu Üriner İnkontinans Sorgulama formu PISQ-12 anketlerin tedavi öncesi ve tedavi sonrası sonuçları değerlendirilmiştir. Bulgular: Tedavi öncesi ve sonrası üroflowmetri parametrelerinden maksimum idrar akım hızında anlamlı azalma izlendi. Tedavi öncesi ve sonrası yapılan KHQ skorlarının değerlendirilmesinde kişiler arası ilişkiler dışında tüm skorlarda anlamlı azalma izlendi. Tedavi öncesi ve sonrası FSFI skorları değerlendirildiğinde anlamlı bir değişiklik olmadığı izlendi. Ancak, diğer yaşam kalite anketleri olan UDI-6, IIQ-7, ICIQ-FLUTS ve PISQ-12de anlamlı bir azalma olduğu ve yaşam kalitesinde olumlu değişim olduğu izlendi. Sonuç: Medikal tedaviye dirençli aşırı aktif mesane sendromu olan hastalarda; intravezikal onabotulinum toksin A enjeksiyonunun kısa dönem sonuçları değerlendirildiğinde hastaların semptom, şikayetlerini azaltmış ve hastaların hayat kalitelerini olumlu yönde arttırmıştır. Bizim hasta grubumuzda komplikasyon gelişmemiş olsa da enfeksiyon ve rezidü idrar artışına bağlı kateterizasyon görülebilmektedir. Medikal tedaviye yanıt alınmayan AAM tedavisinde intravezikal onabotulinum toksin A enjeksiyonu ucuz, kolay uygulanabilir ve ciddi yan etkisi olmayan bir tedavi seçeneği olduğu düşünmekteyiz.

Makale detayları

THE EFFECT OF INTRAVESICAL ONABOTULINUM TOXIN A TREATMENT ON QUALITY OF LIFE IN PATIENTS WITH OVERACTIVE BLADDER

Yazarlar:

Tuğçe Arslanoğlu | Cenk Yaşa | Funda Güngör Uğurlucan

Yayıncı:

Istanbul University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

İstanbul Tıp Fakültesi Dergisi Vol.86 Issue 2, pp.109-116

Belge Tipi:

Makale

Yayın Tarihi:

3/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001287782

pISSN:

1305-6441

Overactive bladder

Onabotulinumtoxin A

Urinary Retention

UrgencyAşırı aktif mesane

onabotulinum toksin A

üriner retansiyon

aciliyet hissi

Sayı

Makale detayları

Yazarlar: Tuğçe Arslanoğlu | Cenk Yaşa | Funda Güngör Uğurlucan

Yayıncı: Istanbul University

Ana Başlıklar: Sağlık Kurumları Yönetimi

Dergi: İstanbul Tıp Fakültesi Dergisi Vol.86 Issue 2, pp.109-116

Belge Tipi: Makale

Yayın Tarihi: 3/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001287782

pISSN: 1305-6441

Sayı

Yazarlar:

Tuğçe Arslanoğlu | Cenk Yaşa | Funda Güngör Uğurlucan

Yayıncı:

Istanbul University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

İstanbul Tıp Fakültesi Dergisi Vol.86 Issue 2, pp.109-116

Belge Tipi:

Makale

Yayın Tarihi:

3/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001287782

pISSN:

1305-6441